Table 1.
Last completed and/or ongoing clinical trials in idiopathic pulmonary fibrosis.
| Drug | Mechanism | Phase | NCT identifier (48) 3 | Ref. |
|---|---|---|---|---|
| Sirolimus (Rapamycin) | Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor | N/A | NCT01462006 | – |
| Omipalisib (GSK2126458) | PI3K/mTOR inhibitor | I | NCT01725139* | (210) |
| HEC68498 | PI3K/mTOR inhibitor | I | NCT03502902 | – |
| Fresolimumab (GC1008) | Anti-TGF-ß monoclonal antibody | I | NCT00125385* | – |
| TD139 | Galectin-3 inhibitor | II | NCT02257177*/NCT03832946 | (211) |
| Tipelukast (MN-001) | Leukotriene antagonist | II | NCT02503657 | – |
| Belumosudil (KD025) | Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor | II | NCT02688647 | (212) |
| CC-90001 | Jun N-terminal kinase inhibitor | II | NCT03142191 | – |
| Dactrekumab (QAX576) | Anti-IL-13 monoclonal antibody | II | NCT00532233*/NCT01266135# | – |
| Lebrikizumab | Anti-IL-13 monoclonal antibody | II | NCT01872689* | (213) |
| Tralokinumab (CAT354) | Anti-IL-13 monoclonal antibody | II | NCT02036580*/NCT01629667# | (214) |
| Romilkimab (SAR156597) | Anti-IgG4 monoclonal antibody that neutralizes IL-4 and IL-13 | II | NCT02345070* | (215, 216) |
| BG00011 (STX-100)§ | Anti-integrin (αvβ6) monoclonal antibody | II | NCT01371305*/NCT03573505# | – |
| Simtuzumab (GS-6624)§ | Anti-lysyl oxidase like-2 (LOXL2) monoclonal antibody | II | NCT01769196# | (217) |
| Ianalumab (VAY-736) | Anti-B-cell activation factor (BAFF) receptor monoclonal antibody | II | NCT03287414 | – |
| Rituximab | Anti-CD20 monoclonal antibody | II | NCT01969409/NCT03286556 | – |
| Carlumab (CNTO 888)§ | Anti-CCL2 monoclonal antibody | II | NCT00786201* | (218) |
| Fezagepras (PBI-4050) | Ligand of probable G-protein coupled receptor (GPR) 40 and 84 | II | NCT02538536* | (219) |
| BMS-986020 | Autotaxin-Lysophosphatidic acid pathway (ATX-LPA) inhibitor | II | NCT01766817* | (220) |
| GLPG1690 | ATX-LPA inhibitor | III | NCT03711162/NCT03733444 | (221) |
| PRM-151 | Pentraxin-2 analogue | III | NCT04552899/NCT04594707 | (158, 222) |
| ART-123 | Recombinant thrombomodulin | III | NCT02739165* | (223) |
| Treprostinil | Prostacyclin | III | NCT04708782 | – |
| Cotrimoxazole | Antimicrobial | III | NCT01777737#/NCT02759120# | (224) |
| Doxycycline | Antimicrobial | III | NCT02759120# | (224) |
| Sildenafil | Phosphodiesterase type 5 (PDE5) inhibitor | III | NCT00517933*/NCT02802345* | (225, 226) |
| Pamrevlumab (FG-3019) | Anti-connective tissue growth factor (CTGF) monoclonal antibody | III | NCT03955146/NCT04419558 | (227) |
*Completed clinical trial.
#Clinical trial withdrawn or terminated.
§Development in IPF discontinued.